Verastem Inc (VSTM)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Brian M. Stuglik |
| Employees: | 50 |
| Web site: | verastem.com |
|
117 KENDRICK STREET, SUITE 500, NEEDHAM, MA, 02494
(781) 292-4200
| |
| Date | Ratio |
|---|---|
| 2023-06-01 | 1:12 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Please log in first to see chart